These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 17206733)

  • 41. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
    Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
    Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Signaling mechanisms that mediate invasion in prostate cancer cells.
    Bonaccorsi L; Marchiani S; Muratori M; Carloni V; Forti G; Baldi E
    Ann N Y Acad Sci; 2004 Dec; 1028():283-8. PubMed ID: 15650253
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
    Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
    Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
    Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening.
    Li S; Sun X; Zhao H; Tang Y; Lan M
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4004-9. PubMed ID: 22595177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects.
    Antonello A; Tarozzi A; Morroni F; Cavalli A; Rosini M; Hrelia P; Bolognesi ML; Melchiorre C
    J Med Chem; 2006 Nov; 49(23):6642-5. PubMed ID: 17154492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation.
    Li J; Kleeff J; Giese N; Büchler MW; Korc M; Friess H
    Int J Oncol; 2004 Jul; 25(1):203-10. PubMed ID: 15202007
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
    Mimeault M; Mehta PP; Hauke R; Henichart JP; Depreux P; Lin MF; Batra SK
    Growth Factors; 2007 Dec; 25(6):400-16. PubMed ID: 18365871
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors.
    Li SN; Xu YY; Gao JY; Yin HR; Zhang SL; Li HQ
    Bioorg Med Chem; 2015 Jul; 23(13):3221-7. PubMed ID: 26003342
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines.
    Mimeault M; Pommery N; Hénichart JP
    Int J Cancer; 2003 Aug; 106(1):116-24. PubMed ID: 12794766
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 4-Anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties.
    Albuschat R; Löwe W; Weber M; Luger P; Jendrossek V
    Eur J Med Chem; 2004 Dec; 39(12):1001-11. PubMed ID: 15571862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
    Cheng W; Yuan Y; Qiu N; Peng P; Sheng R; Hu Y
    Bioorg Med Chem; 2014 Dec; 22(24):6796-805. PubMed ID: 25468044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel dithiocarbamic acid esters derived from 6-aminomethyl-4-anilinoquinazolines and 6-aminomethyl-4-anilino-3-cyanoquinolines as potent EGFR inhibitors.
    Zhang X; Li R; Qiao K; Ge Z; Zhang L; Cheng T; Li R
    Arch Pharm (Weinheim); 2013 Jan; 346(1):44-52. PubMed ID: 23180607
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimization of gefitinib analogues with potent anticancer activity.
    Yin KH; Hsieh YH; Sulake RS; Wang SP; Chao JI; Chen C
    Bioorg Med Chem Lett; 2014 Nov; 24(22):5247-50. PubMed ID: 25305687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2.
    Zhang HQ; Gong FH; Ye JQ; Zhang C; Yue XH; Li CG; Xu YG; Sun LP
    Eur J Med Chem; 2017 Jan; 125():245-254. PubMed ID: 27688180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis of quinazolines as tyrosine kinase inhibitors.
    Srivastava SK; Kumar V; Agarwal SK; Mukherjee R; Burman AC
    Anticancer Agents Med Chem; 2009 Mar; 9(3):246-75. PubMed ID: 19275520
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and evaluation of salicylanilide derivatives as potential epidermal growth factor receptor inhibitors.
    Hu M; Ye W; Li J; Zhong G; He G; Xu Q; Zhang Y
    Chem Biol Drug Des; 2015 Mar; 85(3):280-9. PubMed ID: 24954438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cellular targets of gefitinib.
    Brehmer D; Greff Z; Godl K; Blencke S; Kurtenbach A; Weber M; Müller S; Klebl B; Cotten M; Kéri G; Wissing J; Daub H
    Cancer Res; 2005 Jan; 65(2):379-82. PubMed ID: 15695376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
    Ballard P; Bradbury RH; Harris CS; Hennequin LF; Hickinson M; Kettle JG; Kendrew J; Klinowska T; Ogilvie DJ; Pearson SE; Williams EJ; Wilson I
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4908-12. PubMed ID: 16806916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Targeted molecular therapy: the example of Iressa (ZD1839)].
    Fayette J; Soria JC
    Med Sci (Paris); 2003 Nov; 19(11):1052-4. PubMed ID: 14648471
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.